Rekor Systems (NASDAQ:REKR) Bolsa

Rekor Systems

Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.

Long Ideas

News

Markets

Media

Trading Ideas

CHRD

LRCX

REKR

SOUN

Jim Cramer llama a SoundHound AI una acción meme, su opinión sobre Lam Research y su favorita de energía, Enterprise Products Partners.

SoundHound AI y las recomendaciones de Cramer: ¿Inversión inteligente o especulación?

Advanced Environmental Recycling Technologies

AERT

AILE

CTXR

HONE

HSON

INTZ

KORE

LITM

NATR

PDYN

SLDP

VINC

WATT

Descubre los mayores ganadores y perdedores en el mercado previo tras movimientos impactantes en acciones clave hoy.

Las acciones de Vincerx Pharma (VINC) suben alrededor del 64%; 20 acciones que se mueven en premercado

Rekor Systems Inc

Rekor Systems Inc Warrants(08/11/2023)

Scotiabank analyst Patrick Colville maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Sector Perform and lowers the price target from $275 to $240.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on MongoDB, Lowers Price Target to $240

Walgreens Boots Alliance Agrees To Be Acquired By Sycamore Partners; Total Value Of Transaction Represents Up To $23.7B

Scotiabank analyst Nicholas Yulico maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Sector Perform and lowers the price target from $22 to $21.

Scotiabank Maintains Sector Perform on Macerich, Lowers Price Target to $21

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 14.63% on an annualized basis producing an average annual return of 25.48%. Currently, Veeva Systems has a market capitalization of $37.83 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $9,733.72 today based on a price of $233.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741299310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Amid an especially volatile <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">start to 2025</a>, small-cap stocks have struggled. Are they now a buy at depressed valuations?
Russell 2000: The Russell 2000, as reflected by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), has dropped nearly 15% since December 2024. This constitutes a market correction.
The Trump Administration has embraced domestic and foreign policies that Former Treasury Secretary&nbsp;Larry Summers&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43649860/larry-summers-and-peter-schiff-warn-of-rising-inflation-risks-as-markets-slash-fed-rate-cut-expectations-most-sensitive-moment">labels as inflationary</a>. Higher prices could lead to higher interest rates, which disproportionately affect smaller companies with floating-rate debt.
The Russell index <a href="https://research.ftserussell.com/Analytics/FactSheets/Home/DownloadSingleIssue?issueName=US2000USD&amp;isManual=True">contains</a> 2,000 companies with an average market cap of around $1 billion. Higher-weighted components are likely to have outperformed the rest of the index and are not necessarily representative of the entire Russell 2000. Still, they provide a glimpse into how investors are valuing small-cap companies.
Here&#8217;s how the top stocks in the IWM have performed since the ETF&#8217;s correction began in December 2024:
Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)
<ul>
<li>Dec. 2, 2024, Price: $150.92​</li>
<li>March 6, 2025, Price: $138.11​</li>
<li>Percentage Change: -8.49%</li>
</ul>
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>)
<ul>
<li>Dec. 2, 2024, Price: $72.42​</li>
<li>March 6, 2025, Price: $75.02​</li>
<li>Percentage Change: +3.59%​</li>
</ul>
Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)
<ul>
<li>Dec. 2, 2024, Price: $91.60​</li>
<li>March 6, 2025, Price: $74.81</li>
<li>Percentage Change: -18.33%​</li>
</ul>
SouthState Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NASDAQ">SSB</a>)
<ul>
<li>Dec. 2, 2024, Price: $109.35</li>
<li>March 6, 2025, Price: $92.37</li>
<li>Percentage Change: -15.53%​</li>
</ul>
FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)
<ul>
<li>Dec. 2, 2024, Price: $166.8​</li>
<li>March 6, 2025, Price: $108.2​8</li>
<li>Percentage Change: -35.08%​</li>
</ul>
Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)
<ul>
<li>Dec. 2, 2024, Price: $24.16</li>
<li>March 6, 2025, Price: $18.66</li>
<li>Percentage Change: -22.76%​</li>
</ul>
Applied Industrial Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>)
<ul>
<li>Dec. 2, 2024, Price: $272.91</li>
<li>March 6, 2025, Price: $229.00</li>
<li>Percentage Change: -16.09%​</li>
</ul>
Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)
<ul>
<li>Dec. 2, 2024, Price: $47.80​</li>
<li>March 6, 2025, Price: $42.07</li>
<li>Percentage Change: -11.99%​</li>
</ul>
Ufp Industries Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) and&nbsp;Fluor Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) are also among the ETF&#8217;s top holdings.
Benzinga Edge evaluates stocks on a valuation, momentum and growth basis.
UFP, a holding company based in Grand Rapids, Michigan, performs well under the value criterion, scoring 78.64 out of 100. However, the stock does not have momentum, scoring 32.82. It is also not the fastest-growing company, grading 33.35. The stock is down 20.5% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/UFPI"><img loading="lazy" decoding="async" width="1024" height="229" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png" alt="" class="wp-image-812940" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-300x67.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-768x172.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM.png 1314w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Fluor, an engineering and construction firm, rates high according to its intrinsic value, scoring at 93.6. Still, recent price action indicates its growth and momentum prospects are not high, scoring 15.32 and 29.26, respectively. The stock is down 33.6% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/FLR"><img loading="lazy" decoding="async" width="1024" height="232" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png" alt="" class="wp-image-812935" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-300x68.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-768x174.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li>Unlock the rest of the BZ Edge Rankings and see how <a href="https://www.benzinga.com/quote/fn">another small-cap stock stacks up</a>.</li>
</ul>
S&amp;P 500 Comparison: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks 500 of the largest U.S. companies, has fared slightly better than the Russell 2000. The index is down around 2% since Dec. 2, 2024.
On an earnings basis, investors are trading the S&amp;P 500 at a much higher multiple than the Russell 2000. The S&amp;P as a whole is trading 21.63 times above earnings compared to the small-cap index&#8217;s 14.84 times. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44174230/short-seller-targets-gorilla-technology-group-stock-investors-take-profits">Short Seller Targets Gorilla Technology Group Stock, Investors Take Profits</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Broad U.S. Equity ETFs

ETFs

CRDO

FTAI

INSM

PCVX

RKLB

UFPI

Are Small-Cap Stocks A Buy After Russell 2000 Correction?

Trading Halt: Halted at 5:14:09 p.m. ET - Trading Halt: Halt News Pending

Scotiabank analyst Brandon Bingham maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Sector Outperform and raises the price target from $247 to $254.

Scotiabank Maintains Sector Outperform on Cheniere Energy, Raises Price Target to $254

Scotiabank analyst Brandon Bingham maintains Kinetik Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNTK#NYSE">KNTK</a>) with a Sector Outperform and lowers the price target from $62 to $60.

KNTK

Scotiabank Maintains Sector Outperform on Kinetik Holdings, Lowers Price Target to $60

Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) released its fourth-quarter results after Thursday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/03/b44179559/samsara-reports-fourth-quarter-and-full-fiscal-year-2025-financial-results">from the quarter.</a>
The Details:&nbsp;Samsara reported quarterly earnings of&nbsp;11 cents&nbsp;per share, which beat the analyst consensus estimate of&nbsp;seven cents. Quarterly revenues of $346.3 million beat the analyst consensus estimate of&nbsp;$335.37 million&nbsp;and grew from $276.274 million&nbsp;in the same period last year.
The company also reported ending ARR of $1.458 billion, representing 33% year-over-year adjusted growth, and 2,506 customers with ARR over $100,000, representing 36% year-over-year growth. 
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44172028/trade-turmoil-oil-slides-whats-driving-markets-thursday">Trade Turmoil, Oil Slides: What&#8217;s Driving Markets Thursday?</a>&nbsp;
&#8220;Fiscal year 2025 was another year of durable and efficient growth. We ended the year with close to $1.5 billion of ARR, achieving 33% year-over-year adjusted growth,&#8221; said Sanjit Biswas, CEO of Samsara. &#8220;We&#8217;re operating at a rare combination of growth, scale and profitability, and we see a large market opportunity ahead of us.&#8221;
Outlook: Samsara sees first-quarter EPS between five cents and six cents, versus the five cents estimate, and revenue in a range of $350 million to $352 million, versus the $351.35 million estimate.
IOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Samsara shares were down 3.53% after-hours at $40.40 Thursday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Image: Courtesy of Samsara, Inc.

Earnings

After-Hours Center

Movers

Tech

Samsara Shares Drop Despite Better-Than-Expected Q4 Results

Consolidated copper production for 2025 is expected to range between 75,000 to 85,000 tonnes. The Company remains focused on steadily increasing plant throughput and achieving commercial production at the Tucumã Operation in H1 2025.&nbsp;
As a result, copper production is expected to increase sequentially each quarter, with Tucumã expected to contribute significantly to the full-year consolidated copper production.

Guidance

Ero Copper Expects 2025 Capital Expenditures To Decrease To Range Of $230M - $270M

Scotiabank analyst Phil Hardie maintains First National Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FN#TSX">FN</a>) with a Sector Perform and raises the price target from C$44 to C$45.

TSX:FN

Scotiabank Maintains Sector Perform on First National Financial, Raises Price Target to C$45

Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.31 by 45.16 percent. This is a 19.05 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $122.50 million which missed the analyst consensus estimate of $146.57 million by 16.42 percent. This is a 5.24 percent increase over sales of $116.40 million the same period last year.

Earnings Misses

Ero Copper Q4 2024 Adj EPS $0.17 Misses $0.31 Estimate, Sales $122.50M Miss $146.57M Estimate

Scotiabank analyst Holly Stewart maintains Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) with a Sector Perform and raises the price target from $33 to $35.

Scotiabank Maintains Sector Perform on Enterprise Prods Partners, Raises Price Target to $35

The maximum number of common shares which may be purchased by Sprott during the NCIB will not exceed 645,333 common shares being approximately 2.5% of 25.81 million (representing the number of issued and outstanding common shares as of February 28, 2025).

Buybacks

Sprott Says TSX Approved Notice Of Intention To Make Normal Course Issuer Bid; Plan Not To Exceed 645,333 Common Shares

A federal judge extended an order on Thursday that prevents <a href="https://www.benzinga.com/topic/donald-trump">the Trump administration</a> from freezing billions in congressionally approved funds to 22 states and the District of Columbia.
The New York Times <a href="https://www.nytimes.com/2025/03/06/us/politics/trump-funding-freeze-states.html">reported</a> that the judge found the administration had overstepped in trying to stop the agencies from using money appropriated by Congress.
Judge John J. McConnell Jr. of the Federal District Court for the District of Rhode Island, said in the opinion that the case amounted to executive overreach.
"Here, the executive put itself above Congress," McConnell wrote. "It imposed a categorical mandate on the spending of congressionally appropriated and obligated funds without regard to Congress's authority to control spending."
What Happened: Thursday&#8217;s injunction, the second ordered by a federal court blocking the spending freeze, marks a victory for Democratic attorneys general who filed suit against the Trump administration over its efforts to slash trillions of dollars in order to evaluate whether the programs in question aligned with the president&#8217;s policy goals.
The White House budget office memo that got the ball rolling last month sent millions of workers across the country into a collective state of confusion and insecurity, after which a coalition of state attorneys general launched lawsuits.
The Judge McConnell&#8217;s order, aimed at all the federal agencies cited in the White House memo, directs them to refrain from "pausing, freezing, blocking, canceling, suspending, terminating or otherwise impeding the disbursement of appropriated federal funds to the States under awarded grants, executed contracts or other executed financial obligations."
While the decision represents a rebuke of the spending freeze, <a href="https://www.npr.org/2025/03/06/nx-s1-5312069/trump-federal-funding-freeze-court-order">noted</a> NPR, the preliminary injunction only applies in the states that brought the challenge.
Nevertheless, the ruling was praised by the attorneys general who filed the lawsuit.
&#8220;Americans should feel encouraged that the President cannot impose his will where he does not have the constitutional power to do so. And while he may continue to try, we will continue to fight,&#8221; Rhode Island&#8217;s Attorney General Peter Neronha said&nbsp;<a href="https://riag.ri.gov/press-releases/attorney-general-neronha-recommits-defending-constitution-following-court-decision" target="_blank" rel="noreferrer noopener">in a statement</a>.
"We don't have kings in this country, and today's preliminary injunction reaffirms that&#8221; he continued. "The President's federal funding freeze would be laughable if it wasn't so utterly destructive. It flies in the face of everything we know to be true about our government, namely our separation of powers, by attempting to render the Congress as irrelevant."
<h2 class="wp-block-heading">Trump-Musk Response?</h2>
​As of now, neither President Donald Trump nor Elon Musk, head of the Department of Government Efficiency (DOGE), has issued an official response to the recent decision. However, Musk <a href="https://x.com/elonmusk/status/1897671125775138945">commented </a>on X (formerly Twitter), stating, &#8220;The Democratic government-funded NGO scam might be the biggest theft of taxpayer money ever.&#8221; ​
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Federal Judge Blocks Trump's Freeze On Billions In Congressional Funds: 'Executive Put Itself Above Congress'

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/03/n44179784/broadcom-inc-announces-first-quarter-fiscal-year-2025-financial-results-and-quarterly-dividend">from the quarter</a>.
Q1 Earnings: Broadcom reported first-quarter revenue of $14.92 billion, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $14.61 billion, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The semiconductor company reported first-quarter adjusted earnings of $1.60 per share, beating analyst estimates of $1.49 per share.
Total revenue was up 25% on a year-over-year basis, driven by strength in AI semiconductor solutions and infrastructure software. Broadcom generated $6.11 billion in cash from operations and $6.01 billion in free cash flow during the quarter. The company ended the quarter with approximately $9.31 billion in cash and cash equivalents.
&#8220;Q1&nbsp;AI revenue grew&nbsp;77%&nbsp;year-over-year to&nbsp;$4.1 billion&nbsp;and infrastructure software revenue grew&nbsp;47%&nbsp;year-over-year to&nbsp;$6.7 billion,&#8221; said&nbsp;Hock Tan, president and CEO of Broadcom.
&#8220;We expect continued strength in AI semiconductor revenue of&nbsp;$4.4 billion&nbsp;in&nbsp;Q2, as hyperscale partners continue to invest in AI XPUs and connectivity solutions for AI data centers.&#8221;
Broadcom&#8217;s board approved a quarterly cash dividend of 59 cents per share, payable on March 31 to shareholders of record as of March 20.
See Also: <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a>
Outlook: Broadcom expects second-quarter revenue of approximately $14.9 billion, versus estimates of $14.76 billion. The company anticipates first-quarter adjusted EBITDA of approximately 66% of projected revenue.
Broadcom executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
AVGO Price Action: <a href="https://www.benzinga.com/quote/AVGO" target="_blank" rel="noreferrer noopener">Broadcom shares</a> were up 8.73% after hours, trading at $195.11 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

AVGO

Broadcom Stock Surges On Q1 Earnings Beat, Revenue Beat, Strong Guidance: 'We Expect Continued Strength In AI Semiconductor Revenue'

BRBR

BellRing Brands Board Approves $300M Share Repurchase Authorization Over Next Two Years

Throughout the last three months, 4 analysts have evaluated EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $30.25, with a high estimate of $33.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 3.14% increase from the previous average price target of $29.33.
<img src="https://www.benzinga.com/files/images/story/2025/1741298458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of EyePoint Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$33.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to EyePoint Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EyePoint Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into EyePoint Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EYPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EyePoint Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into EyePoint Pharmaceuticals's Background</h2>
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
<h3>EyePoint Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, EyePoint Pharmaceuticals faced challenges, resulting in a decline of approximately -30.77% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: EyePoint Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -278.99%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): EyePoint Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of -13.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): EyePoint Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.39%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, EyePoint Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews

Discover Financial servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.52%. Currently, Discover Financial servs has a market capitalization of $43.44 billion. 
Buying $100 In DFS: If an investor had bought $100 of DFS stock 5 years ago, it would be worth $315.32 today based on a price of $172.67 for DFS at the time of writing.
<h3>Discover Financial servs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741298419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Discover Financial servs 5 Years Ago Would Be Worth Today

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) sees Q1 sales of $33.000 million-$35.000 million vs $35.38 million analyst estimate.

ASUR

Asure Software Sees Q1 Sales $33.000M-$35.000M vs $35.38M Est

Press Releases

"Breakthrough Stocks to Watch: WATT, STEM, PNPN.V, NXU, REKR Powering Santa Rally Momentum, more inside!"

Rekor Systems Fully Satisfies Outstanding Balance from Yorkville Advisors

New Mexico Department of Transportation Expands Use of Rekor Discover™ Through Pay-for-Data Distribution Model

Rekor Unveils Industry's First AI-Powered Traffic Incident Priority Ranking in Rekor Command™ Platform for Faster Emergency Response and Roadway Safety.

Rekor Systems Taps SoundHound AI to Revolutionize Emergency Vehicle Technology With First Of Its Kind Audio-Visual AI

Rekor Scout® Certified for New Jersey's $13M Public Safety Initiative, Empowering Law Enforcement with Advanced Technology

Rekor Systems Secures European Patent for Advanced Technology to Detect and Mitigate Irregular Traffic Congestion

Rekor Systems to Participate in the 37th Annual Roth Conference

Rekor Systems to Announce 2024 Results

Rekor's Vehicle Insite Application Deployed to Study Electric Vehicle Movement Across 90 Sites in the Phoenix Metropolitan Area

KAVL

PNPNF

PRSO

STEM

TNXP

TSXV:PNPN

AudioEye

ReAlpha Tech

Arqit Quantum

CoreCard

Cheetah Mobile Inc. American Depositary Shares, each representing fifty (50) Class A Ordinary Shares

Cheetah Mobile

Viant Technology

eGain

Inuvo

Aurora Mobile Limited - American Depositary Shares

Aurora Mobile

LivePerson

WM Technology, Inc. - Class A Common Stock

WM Tech

The9 Limited - American Depository Shares

The9

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

Rekor Systems

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL